Protagonist Therapeutics (US:PTGX) — Company Overview, News & Financial Data
Protagonist Therapeutics focuses on innovative peptide-based drugs for gastrointestinal disorders and unmet medical needs.
Protagonist Therapeutics
Protagonist Therapeutics (NASDAQ:PTGX) is a biotechnology firm focused on discovering and developing innovative peptide-based drugs. Their operation spans the spectrum from early research to clinical development, with a particular emphasis on treating diseases by targeting the body's protein interactions. Their projects often revolve around gastrointestinal disorders, anemia, and other diseases where there is a significant unmet medical need. The objective of Protagonist Therapeutics is to leverage their proprietary technology platforms to create therapies that improve patient outcomes and potentially lead to better quality of life. The company is constantly exploring new avenues for their drug development process, aiming to expand their portfolio and impact on healthcare significantly.
Snapshot
Operations
Products and/or services of Protagonist Therapeutics
- Rusfertide (PTG-300) is an injectable hepcidin mimetic in development for polycythemia vera and other blood disorders.
- PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin antagonist aimed at treating inflammatory bowel diseases.
- PTG-200 (JNJ-67864238) is an oral IL-23 receptor antagonist, co-developed with Janssen Biotech, targeting Crohn's disease and ulcerative colitis.
- PTG-100 is an oral peptide a4ß7 integrin antagonist being studied for potential treatment of ulcerative colitis.
- Rusfertide for hereditary hemochromatosis aims to reduce blood iron levels, offering a novel treatment option.
- Collaboration with Janssen Biotech focuses on the discovery and development of new integrin receptor antagonists for gastrointestinal diseases.
Protagonist Therapeutics executive team
- Dr. Dinesh V. Patel Ph.D.CEO, President, Secretary & Director
- Mr. Asif AliExecutive VP & CFO
- Dr. Suneel K. Gupta Ph.D.Executive Vice President of Clinical Development
- Dr. Arturo M. Molina FACP, M.D., M.S.Chief Medical Officer
- Mr. Mohammad Masjedizadeh Ph.D.Executive VP & CTO
- Dr. Newman YeildingExecutive VP, Chief Scientific Officer
- Mr. Matthew M. Gosling J.D.Executive VP and Chief Legal & Business Officer
- Ms. Carena SpiveySenior VP & Chief Human Resources Officer
- Dr. Ashok Bhandari Ph.D.EVP & Chief Discovery Officer
- Mr. Carter J. KingExecutive Vice President of Business Development